

Fax completed prior authorization request form to 855-247-3677 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

All requested data must be provided. Incomplete forms or forms without the chart notes will be returned

Pharmacy Coverage Guidelines are available at www.mercycareaz.org/providers/pharmacy.html

Growth Hormone & Growth Stimulating Agents Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently.

REQUIRED: Chart notes that include weight, height, growth velocity and lab values (GH levels, IGF-1 / IGFBP-3), stim test results, bone age Member Information

Member Name (first & last):						Date of Birth:				Gender:			Height: Female						
Member ID:						City	/:			State	e:			W	Weight:				
Prescribing Pro	vide	r Information																	
Provider Name (first & last): Specia										NPI#	NPI#			DEA#					
Office Address:					City:					State	State:			Zip Code:					
Office Contact:					Office	Pho	ne				Office Fax:								
Dispensing Pha		cy Information																	
Pharmacy Name	:					Pha	armacy I	Phone	ə:				Pharma	acy Fax:					
Requested Med	icatio													T					
Preferred Agents:		Genotropin or	Geno	tropin Mi	niQuick] Nord	ditrop	in Fl	exPro		Brand O	mnitrope		□ Brand Zomacton				
Non-Preferred		Humatrope		Increle	< [J N	Igenla			Nutropr	rin A(ຊ Nuspin		Saizen o	izen or Saizen Click Easy				
Agents:		Serostim		Skytrof	a 🗆] S	Sogroya			Zorbtive	е								
Other Please Specify:																			
Are there any co (if yes, please sp			nular	y medica	tions?					ΠY	'es	□ No				Continuation of therapy			
Medication reque	est is	NOT for an FDA	A-app	roved, or	compe	ndia	-	Wha	t me	dication	(s) ha	ave been t	tried and	failed fo	r this c	liagnosis?			
Medication request is NOT for an FDA-approved, or compendia- supported diagnosis (circle one): Yes No								(please specify):											
																of chart notes			
							or verification of paid claims documenting his preferred products listed below (please chec							of fail	ure to ALL				
								p		-		tropin/Ger			k				
						Brand Norditropin FlexPro						κPro							
											Brand Omnitrope Brand Zomacton								
What is the diagr	nosis	ICD-10 Code?						Diag	nosi		20ma								
Directions for Us	e:				[Strength:								Dosage Form:					
						Qua	antity:			Day S	upply	/:	Duration of 1		rapy/L	se:			
						-													
Turn-Around Ti				16	041	,				•			116	10	1 1110 1	÷			
□ Standard – hours)	(24			n function								ously harr	n life, hea	alth, or a	ibility to	o regain			
		Sigr	nature	e:															
Clinical Informa	tion	<u> </u>																	

Pediatric Growth Hormone Deficiency												
Current height: Date Obtained:												
Does the member have history of neonatal hypoglycemia associated with pituitary disease?												
DX is pediatric	Projected height	>2 SD belov	w mid-parent	al height using age A	ND gender growth cha	rts related to h	neight					
GH deficiency	□ Height is >2.25 S	D below po	pulation mea	in using age and geno	der growth charts relate	ed to height						
confirmed by Image: Confirmed by ONE of the Image: Confirmed by Growth velocity is >2 SD below mean for age and gender												
following:	Delayed skeletal maturation >2 SD below mean for age AND gender											
\Box Male with hope are <16 years?												
□ Male with bone age <16 years?												
Documentation of TWO of the following GH stimulating tests with BOTH response Arginine Clonidine values <10 mcg/L? 												
0	Levodopa 🗆 Glucagon											
Age <1 year ANI	D IGF-1 OR IGFBP-3 is	helow are	AND gender	adjusted normal rand	e as provided by physi	cian's lab	□ Yes	□ No				
• •	eed MAX supply limit	-			stage 3 or greater AND							
of 0.3 mg/kg/wk?					X supply limit of 0.7 m							
□ Renewal Re	•											
Documentation c	of height increase by at	least 2cm/yr										
current height date obtained:												
Is there documer	s there documentation showing 🛛 Yes 🗋 No Is there documentation of expected adult height goal 🖓 Yes 🖾 No											
	expected adult height not attained? (genetic potential)?											
Documentation c	Documentation of calculated height GV over the past 12 months?											
Male with bone <	ale with bone <16 years? □ Yes □ No □ N/A Female with bone age <14 □ Yes vears?							□ N/A				
-	Does dosing exceed a MAX supply limit							🗆 No				
of 0.3mg/kg/wk? does NOT exceed MAX supply limit of 0.7mg/kg/wk?												
Current Height: Date obtained:												
Renewal Request ONLY: A standard stand												
mass)?	Is there documentation of evidence of positive response to therapy (increase in total lean body mass, decrease in fat Mass)?											
'	ntation of height increas	se by at leas	t 2cm/yr ove	r the previous year of	TX?							
Current height:				Date obtaine	d:							
Is there documer		□ Yes	□ No I	s there documentatio	n of expected adult hei	ght goal	□ Yes	🗆 No				
	eight not attained?		((genetic potential)?								
Turner Syn												
•	iatric growth failure Furner Syndrome?	□ Yes	🗆 No	is the member a fe	emale AND bone age is	s < 14 years?	□Yes	□No				
	he 5th percentile on gro	owth charts f	or age AND	gender?			□Yes	□No				
□ Renewal Re	equest ONLY:											
	ntation of height increas	e by at leas	t 2cm/yr ove	r the previous year of	TX?							
Current height:	Current height: Date obtained:											
Is there documer		□ Yes	□ No I		n of expected adult hei		□ Yes	□ No				
	eight not attained?			(genetic potential)?	-							
□ Noonan Sy		<u> </u>	<u> </u>	1 - ···· 1 · ··								
Is the member a years?	male with bone age <1	6 🗆 Ye	es □ No		member a female with age <14 years?	□Yes	□ No	□ N/A				
Height is below t	he 5th percentile on gro	owth charts f	or age and g	jender?			□Yes	□No				
Current Height:				Date obtaine	ed:							
	equest ONLY:											
Is there documer	ntation of height increas	se by at leas	t 2cm/yr ove	r the previous year of	TX?							
Current height: _				Date obtaine	d:							

Effective: 06/01/2024 C22938-A 05-2024

Is there documentation showing	□ Yes □ N							adult heig	ht goal	□ Yes	🗆 No				
expected adult height not attained?	aianay				(genetic potential)?										
Is the diagnosis confirmed by genetic												□ Yes	□ No		
Is the member a male with bone age		-	Yes		No		N/A	Is the member a fe	mala	with					
years?	9 < 10	Ц	res		No		N/A	bone age <14 year		with	□Yes	□ No	□ N/A		
Current Height: Date obtained:															
Renewal Request ONLY:															
Is there documentation of height incl	rease b	y at lea	ast 2c	m/yr	over t	he pre	vious	year of TX?				□ Yes	🗆 No		
Current height:							Date	obtained:							
Is there documentation showing expected adult height not attained?											□ Yes	🗆 No			
expected adult height not attained?	Ronal I	nsuffi	riency			(gene	etic p	otential)?							
Growth Failure with Chronic Renal Insufficiency															
Current Height:								obtained:							
Is the member a male with bone age years?	e <16	<u> </u>	Yes		No		N/A	Is the member a fe bone age <14 year		with	□Yes	□ No	□ N/A		
Renewal Request ONLY:															
Is there documentation of height inci		-	ast 2c	m/yr	over t	he pre	vious	year of TX?							
Current height:								obtained:					-		
Is there documentation showing		□ Ye	es		lo			cumentation of expe	ected a	adult heig	ht goal	□ Yes	🗆 No		
expected adult height not attained?	nall for	Gosta	ationa		<u> </u>	(gene	etic p	otential)?							
Growth Failure in Children Small for Gestational Age															
Current Height: Date obtained:															
Diagnosis of small for gestational age (SGA) based on demonstration of catch-up growth failure in the first 24 months of life using a 0-36-month growth chart?										□ Yes	🗆 No				
Is member below the 3rd percentile for \Box Yes \Box N						Is the	re do	cumentation that hei	ight re	mains eq	ual to	□ Yes	□ No		
gestational age (>2 standard deviations						OR below 3rd percentile (≥ 2 standard deviations									
below population mean) for birth wei					below	elow population mean)?									
AND length? Renewal Request ONLY:															
Is there documentation of height incr	aasa h	w at les	ast 2c	m/vr	over t	he nre	vious	vear of TX2				□ Yes	□ No		
		y at lot	401 20	· · · · y ·	0001			-							
Current height:								obtained:							
Is there documentation showing expected adult height not attained?		□ Ye	es		No			cumentation of expe otential)?	ected a	adult heig	ht goal	□ Yes	🗆 No		
□ Transition Phase Adolescent	Memb	ers		<u> </u>		(3									
Does the dose exceed MAX limit of ().3mg/l	kg/wk?										🗆 Yes	🗆 No		
Is there documentation that member	attaine	ed	□ Ye	es				e documentation of b	□ Yes	□ No					
expected adult height? Member is at high risk of GH		nbryopa	athic /	conc	nonita		1	g closed epiphyses? Genetic mutations		At least 3	ies of the fo	llowing			
deficiency due to childhood-onset	defect		aune /	cong	Jenna							ficiencies of the following tary hormones:			
from ONE of the following:		versibl	e stru	ctura	1			Panhypopituitarism		⊐ FSH	-				
	hypot	halami	c-pitui	itary o	diseas	se		51 1		⊐ TSH					
										⊐ ACT⊦ ⊐ Prola					
Is IGF-1/Somatomedin-C level belov	v age A	ND	□ Ye	es.			oes r	nember have a low lo				□ Yes	□ No		
gender adjusted normal range as pro							vel?		,						
physician's lab? Member has stopped GH therapy for at least ONE						Insulin Tolerance Test: Glucagon: A									
month AND undergone ONE provocative GH stim test						5 ng/m	≤0.4 ng/mL								
confirming transition phase GH deficiency AND ONE						inine +	GHF	<u>RH</u> :							
of the following peak values:	□ ≤11 ng/mL if BMI is < 25 kg/m2														
	□ ≤8 ng/mL if BMI ≥25 and <30 kg/m2														
	□ ≤4 ng/mL if BMI ≥30 kg/m2 Has the member discontinued GH therapy for at least 1														
Is the member at low risk of severe] Yes		NO			mbe	discontinued GH the	erapy	tor at lea	st 1	□ Yes	🗆 No		
GH deficiency (due to isolated and/or month? idiopathic GH deficiency)?															

Has the member undergor D/C of therapy for at least	after	דדו ם	G	HRH	& ARG		RG		Glu	ucagon					
Is ITT ≤5mcg/L? □ Y	Is GHRH and ARG ≤11 micg/L if BMI <25 KG/M2?										Yes	[⊐ No		
	•						f BMI ≥25 ar		g/m2?				Yes	[⊐ No
												Yes	[⊐ No	
ls glucagon ≤3 mcg/L?			Yes		No										
Is ARG ≤0.4mcg/L?			Yes		No										
Renewal Request OI															
Is there documentation sur (Increase in total lean body					R incre	eased	IGF-1 and I	GFBP-3 I	levels	?			□Yes		□No
Request does not exceed	a MAX supply lin	nit of 0.3	mg/kg/	wk?			Yes			0					
Adult Growth Hormo	one Deficiency								1						
Is there a diagnosis of child	dhood-onset GHI)?	□Ye	s □1	No	Is there	e a diagnosi	s of adul	lt-onse	et GHD?			□Yes		□No
Is there documentation sur	oporting hormone	;	□Ye	s ⊡l	Vo V	Was th	nere 1 GH st	im test c	onfirm	ning adult	t GH		□Yes		□No
deficiency is due to hypoth							ncy (insulin								
disease from organic or kn	own causes?					glucag	on, arginine)?							
Member has ONE of the	Insulin toleranc	e test:	Argin	ine+G⊦	IRH:				(Glucagor	ו:	Α	rginine	e:	
following peak value	□ ≤5 ng/ml		□ ≤1	1 ng/ml	_ if BN	∕II is <	25 kg/m2		[⊐ ≤3 ng/ı	mL] ≤0.4	ng/r	nL
tests:			□ ≤8	ng/mL	if BMI	l ≥25 a	nd <30 kg/n	า2							
			□ ≤4	ng/mL	if BMI	l ≥30 k	g/m2								
Is there deficiency of at lea	ast 3 anterior pitu	itary	□Ye	s ⊡l	١o	Is IG	-1/Somator	medin-C	level i	s below a	age ANI	D	□Yes		□No
hormones (FSH/LH, TSH,	ACTH, Prolactin)	?				-	er adjusted ı cian's lab?	normal ra	ange a	is provide	ed by				
Diagnosis of panhypopituit	arism?		□Ye	s ⊡l	١o		ber has othe	er diagno	sis an	d will not	tuse		□Yes		□No
				-	th hormone i tors or Andr										
Request does not exceed	a maximum supp	ly limit	□ Ye	s 🗆	No	Prescribed by an Endocrinologist?							□ Yes		□ No
of 0.3 milligrams per kilogr	,	<u> </u>				,		5				_ 100			
Renewal Request ONLY:															
Documentation of IGF-1/S	month	ns?							□Yes		□No				
Diagnosis of panhypopituit	□Ye		No	Mem	ber has othe	er diagno	sis an	d will not	lise		□Yes	_	□No		
Diagnoolo of parinypophan		5	NO		th hormone i										
							tors or Andr								
Request does not exceed	a maximum supp	ly limit	□ Ye	s 🗆	No		cribed by an	•	nologi	st?			□ Yes		□ No
of 0.3 milligrams per kilogr		-					-		•						
HIV-Associated or W	lasting Syndron	ne or Ca	chexia	3	1	<u>.</u>									
Has there been unintentior	nal weight loss of	greater	than 1	0% ove	r the I	last 12	months?						□Yes		□No
Has there been unintention of >7% over the last 6 mor	•	□Yes	□N	□No Has there been a loss of 5% BCM within 6 months?								□ Yes	;	□ No	
Is BMI <20 kg/m2?	1015 :	□Yes	□N	□No Is the member male with BCM<35% of total body weight									□ Yes	;	□ No
Is the member a female wi	th BCM < 23%	□Yes	□N				kg/m2? mal evaluatio	on comp	leted s	since the	onset o	of	□ Yes		□ No
of total body weight and Bl	MI <27 kg/m2?			wasting first occurred?											
Was there weight loss as a underlying treatable condit		□Yes	□N		ras the		retroviral the	erapy opt	imized	a to decre	ease the	9	□ Yes	;	□ No
Renewal Request OI				VI		au :									
-			Joh			Na	Mag apy	of the ter	acto o	r goolo	huch		Vaa		
Is there evidence of positiv as ≥2% increase in body w		JCH	□Yes		No	Was any o as weight,		-	-	sucri		Yes		□ No	
Short Bowel Syndro					1 -					=	1.0	Τ=			
Is member currently receiving specialized nutrition support (IV parenteral nutrition, fluid AND micronutrie				□Yes		No		Vas 4 weeks of treatment with Zorbtive reviously received?				Yes	l	□ No	
supplements)? Severe Primary IGF-1 Deficiency / Growth Hormone Gene Deletion															
current height:					ent da										
Is the height standard devi	ation score ≤-3.0	?										□ Yes			□ No
Is the basal IGF-1 standard		□Yes		□No	Is there normal or elevated growth hormone levels?						Yes	[□ No		

Is there documentation of open epiphyses on last bone radiograph?	□Yes	□No	Will member be treated with concurrent growth hormone therapy?	□ Yes	□ No						
Is there a diagnosis of growth hormone gene deletion AN	□Yes	□No									
hormone?											
Submission of documentation of height increase of at lea	□ Renewal Request ONLY: Submission of documentation of height increase of at least 2cm/yr □ Yes										
	-										
current height:											
Is there documentation showing expected adult height	□ Yes	🗆 No	Is there documentation of expected adult height goal (genetic potential)?	□ Yes	□ No						
not attained? Additional information the prescribing provider feels	it modical re	oordo									
Additional mormation the prescribing provider leeps	is importa		review. Flease specify below of subm	it metical re	corus						
Signature affirms that information given on this form	is true and	accurat	e and reflects office notes.								
Prescribing Provider's Signature:			Date:								

Please note: Incomplete forms or forms without the chart notes will be returned

Office notes, labs, and medical testing relevant to the request that show medical justification are required. Standard turnaround time is 24 hours. You can call 800-564-5465 to check the status of a request.